10/ 613,782

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

10/ 613,782

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:37:17 ON 19 MAY 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:37:32 ON 19 MAY 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4
DICTIONARY FILE UPDATES: 18 MAY 2005 HIGHEST RN 850688-83-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10613782.str



chain nodes :
12 14 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11

chain bonds :
5-12 6-14 7-11 9-16
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
exact/norm bonds :
5-12 6-14 7-11 9-16
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:O,N

G2:H,X,Ak

G3:Ak,NH2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 14:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N

G2 H,X,Ak

G3 Ak,NH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample
SAMPLE SEARCH INITIATED 16:38:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1855 TO ITERATE

53.9% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10/ 613,782

BATCH **COMPLETE**
PROJECTED ITERATIONS: 34517 TO 39683
PROJECTED ANSWERS: 1 TO 118

L2 1 SEA SSS SAM L1

=> d scan l2

10/ 613,782

L2 1 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinazoline, 7-(cyclopropylmethoxy)-2-methyl-4-(1-pyrrolidinyl)- (9CI)
MF C17 H21 N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/ 613,782

=> s l1 full
FULL SEARCH INITIATED 16:39:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 37212 TO ITERATE

100.0% PROCESSED 37212 ITERATIONS 36 ANSWERS
SEARCH TIME: 00.00.02

L3 36 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	162.19	162.40

FILE 'CAPLUS' ENTERED AT 16:39:15 ON 19 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 May 2005 VOL 142 ISS 21
FILE LAST UPDATED: 18 May 2005 (20050518/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:41451 CAPLUS
DOCUMENT NUMBER: 140:111423
TITLE: Quinazoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly antagonists, their preparation and pharmaceutical compositions, and their use in the treatment of, e.g. obesity
INVENTOR(S): Mattei, Patrizio; Mueller, Werner; Neidhart, Werner; Nettekoven, Matthias Heinrich; Pflieger, Philippe
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005265	A1	20040115	WO 2003-EP6868	20030627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489251	AA	20040115	CA 2003-2489251	20030627
US 2004029901	A1	20040212	US 2003-613782	20030703
PRIORITY APPLN. INFO.:			EP 2002-14904 A	20020705
			WO 2003-EP6868 W	20030627

OTHER SOURCE(S): MARPAT 140:111423
GI



AB Title compds. I and their pharmaceutically acceptable salts and esters can be used in the form of pharmaceutical prepns. for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders, and obesity [wherein: R1 = OR4 or NR5R6; = alkyl or

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

amino; R3 = H, alkyl, or halogen; R4 = H, alkyl, alkoxyalkyl, hydroxyalkyl, aralkyl, heterocyclylalkyl, cycloalkylalkyl, amino-SO2-, or alkyl-SO2-; R5, R6 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcarbonyl, cycloalkylcarbonyl, aryl, aralkyl, arylcarbonyl, alkoxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, alkyl-SO2-, aryl-SO2-, heterocyclyl-SO2-, or amino-SO2-; or NR5R6 = 5- to 10-membered heterocyclic ring with optional addnl. N or O atom, and optionally substituted with alkyl and/or alkoxy; NRR' = 5- to 7-membered satd. heterocyclic ring optionally contg. a second heteroatom (O, N, or S) and, optionally substituted by halogen, alkyl, alkoxy, haloalkoxy, cycloalkylalkoxy, hydroxy, amino, acetylamino, cyano, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, and cycloalkylalkoxyalkyl]. I are neuropeptide ligands; more specifically, they are selective neuropeptide Y (NPY) antagonists, and in particular, they are antagonists for the Y5 receptor subtype. Approx. 34 specific examples were prepd., and 10 of these are claimed. For instance, 4-bromoanthranilic acid was cyclocondensed with acetyl chloride to give 99.4% 7-bromo-2-methyl-3H-quinazolin-4-one, which was treated with POCl3 and PhNMe2 to give 59% 7-bromo-4-chloro-2-methylquinazoline. Aminolysis of this dihalide, first with pyrrolidine at the 4-position (100%), and then with isobutylamine at the 7-position, gave a preferred invention compd., II. In tests for displacement of labeled peptide YY (PYY) from mouse brain NPY5 receptors expressed in HEK 293 cells, compd. II had an IC50 value of 3 nM.

IT **646450-52-4P**, 7-Benzyloxy-2-methyl-4-pyrrolidin-1-ylquinazoline **646450-53-5P**, 2-Methyl-4-pyrrolidin-1-ylquinazolin-7-ol **646450-66-0P**, (S)-[1-(7-Benzyloxy-2-methylquinazolin-4-yl)pyrrolidin-2-yl]methanol **646450-67-1P**, (S)-4-(2-Hydroxymethylpyrrolidin-1-yl)-2-methylquinazolin-7-ol **646450-73-9P**, (S)-7-Benzyloxy-4-(3-ethoxypyrrolidin-1-yl)-2-methylquinazoline **646450-74-0P**, (S)-4-(3-Ethoxypyrrolidin-1-yl)-2-methylquinazolin-7-ol **646450-76-2P**, (S)-1-(7-Benzyloxy-2-methylquinazolin-4-yl)pyrrolidin-3-ol **646450-77-3P**, (S)-4-(3-Hydroxypyrrolidin-1-yl)-2-methylquinazolin-7-ol
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinazoline derivs. as NPY antagonists for
treatment of obesity, etc.)

RN 646450-52-4 CAPLUS
CN Quinazoline, 2-methyl-7-(phenylmethoxy)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-53-5 CAPLUS
CN 7-Quinazolinol, 2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-66-0 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[2-methyl-7-(phenylmethoxy)-4-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-67-1 CAPLUS
CN 7-Quinazolinol, 4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-73-9 CAPLUS
CN Quinazoline, 4-[(3S)-3-ethoxy-1-pyrrolidinyl]-2-methyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-74-0 CAPLUS
CN 7-Quinazolinol, 4-[(3S)-3-ethoxy-1-pyrrolidinyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-76-2 CAPLUS
CN 3-Pyrrolidinol, 1-[2-methyl-7-(phenylmethoxy)-4-quinazolinyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-77-3 CAPLUS
CN 7-Quinazolinol, 4-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 646450-56-8P, 4-[[[2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]oxy]methyl]benzonitrile 646450-58-0P, 7-(2-Chloropyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-ylquinazoline 646450-61-5P, 2-[[[2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]oxy]methyl]benzonitrile 646450-62-6P, 7-(2-Fluoropyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-ylquinazoline 646450-63-7P, 5-[[[2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]oxy]methyl]pyridine-2-carbonitrile 646450-64-8P, 7-Cyclopropylmethoxy-2-methyl-4-pyrrolidin-1-ylquinazoline hydrochloride 646450-65-9P, 4-[[2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]oxy]benzonitrile 646450-68-2P, (S)-4-[[[4-(2-Hydroxymethylpyrrolidin-1-yl)-2-methylquinazolin-7-yl]oxy]methyl]benzonitrile 646450-69-3P, (S)-[1-[7-(2-Chloropyridin-3-ylmethoxy)-2-methylquinazolin-4-yl]pyrrolidin-2-yl]methanol 646450-70-6P, (S)-[1-[7-(2-Fluoropyridin-3-ylmethoxy)-2-methylquinazolin-4-yl]pyrrolidin-2-yl]methanol 646450-71-7P, (S)-5-[[[4-(2-Hydroxymethylpyrrolidin-1-yl)-2-methylquinazolin-7-yl]oxy]methyl]pyridine-2-carbonitrile 646450-72-8P, (S)-[1-[7-(Cyclopropylmethoxy)-2-methylquinazolin-4-yl]pyrrolidin-2-yl]methanol 646450-75-1P, (S)-4-[[[4-(3-Ethoxypyrrolidin-1-yl)-2-methylquinazolin-7-yl]oxy]methyl]benzonitrile 646450-79-5P, (Cyclopropylmethyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-80-8P, (Isobutyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-81-9P, (2,2-Dimethylpropyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-82-0P, (2-Chlorobenzyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-83-1P, (2-Methylbenzyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-84-2P, 4-[[2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amino]benzonitrile 646450-85-3P, (4-Fluorophenyl)[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amine 646450-86-4P, [2-Methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl](pyridin-3-yl)amine 646450-87-5P, Furan-2-carboxylic acid N-[2-methyl-4-(pyrrolidin-1-yl)quinazolin-7-yl]amide 646450-88-6P, (S)-[4-(3-Ethoxypyrrolidin-1-yl)-2-methylquinazolin-7-yl](pyridin-3-yl)amine 646450-89-7P, (S)-[4-(3-Ethoxypyrrolidin-1-yl)-2-methylquinazolin-7-yl](4-fluorophenyl)amine 646450-90-0P, (S)-[4-(3-Methoxypyrrolidin-1-yl)-2-methylquinazolin-7-yl](pyridin-3-yl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazoline derivs. as NPY antagonists for

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
treatment of obesity, etc.)

RN 646450-56-8 CAPLUS
CN Benzonitrile, 4-[[[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 646450-58-0 CAPLUS
CN Quinazoline, 7-[(2-chloro-3-pyridinyl)methoxy]-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-61-5 CAPLUS
CN Benzonitrile, 2-[[[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 646450-62-6 CAPLUS
CN Quinazoline, 7-[(2-fluoro-3-pyridinyl)methoxy]-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-63-7 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[[[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 646450-64-8 CAPLUS
CN Quinazoline, 7-(cyclopropylmethoxy)-2-methyl-4-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 646450-65-9 CAPLUS
CN Benzonitrile, 4-[[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-68-2 CAPLUS
CN Benzonitrile, 4-[[[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-methyl-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-69-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[7-[(2-chloro-3-pyridinyl)methoxy]-2-methyl-4-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-70-6 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[7-[(2-fluoro-3-pyridinyl)methoxy]-2-methyl-4-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-71-7 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[[[4-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-2-methyl-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-72-8 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[7-(cyclopropylmethoxy)-2-methyl-4-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-75-1 CAPLUS
CN Benzonitrile, 4-[[[4-[(3S)-3-ethoxy-1-pyrrolidinyl]-2-methyl-7-

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-82-0 CAPLUS
CN 7-Quinazolinamine, N-[(2-chlorophenyl)methyl]-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-83-1 CAPLUS
CN 7-Quinazolinamine, 2-methyl-N-[(2-methylphenyl)methyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-84-2 CAPLUS
CN Benzonitrile, 4-[[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-79-5 CAPLUS
CN 7-Quinazolinamine, N-(cyclopropylmethyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-80-8 CAPLUS
CN 7-Quinazolinamine, 2-methyl-N-(2-methylpropyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-81-9 CAPLUS
CN 7-Quinazolinamine, N-(2,2-dimethylpropyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 646450-85-3 CAPLUS
CN 7-Quinazolinamine, N-(4-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-86-4 CAPLUS
CN 7-Quinazolinamine, 2-methyl-N-3-pyridinyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 646450-87-5 CAPLUS
CN 2-Furancarboxamide, N-[2-methyl-4-(1-pyrrolidinyl)-7-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 646450-88-6 CAPLUS
CN 7-Quinazolinamine, 4-[(3S)-3-ethoxy-1-pyrrolidinyl]-2-methyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 646450-89-7 CAPLUS
CN 7-Quinazolinamine, 4-[(3S)-3-ethoxy-1-pyrrolidinyl]-N-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646450-90-0 CAPLUS
CN 7-Quinazolinamine, 4-[(3S)-3-methoxy-1-pyrrolidinyl]-2-methyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:172597 CAPLUS
DOCUMENT NUMBER: 130:209716
TITLE: Preparation of 2-vinyl-4-aminoquinazoline derivatives as insulin secretion promoters and antidiabetics
INVENTOR(S): Ueno, Kimihisa; Nomoto, Yuji; Takasaki, Kotaro; Yoshida, Miho; Kusaka, Hideaki; Yano, Hiroshi; Nakanishi, Satoshi; Matsuda, Yuzuru; Uesaka, Noriaki; Suzuki, Chiharu
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan; et al.
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909986	A1	19990304	WO 1998-JP3711	19980821
W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9887487	A1	19990316	AU 1998-87487	19980821
PRIORITY APPLN. INFO.:			JP 1997-225963 A	19970822
			WO 1998-JP3711 W	19980821

OTHER SOURCE(S): MARPAT 130:209716
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Claimed are insulin secretion promoters and remedies for diabetes which contain as the active ingredient 2-vinyl-4-aminoquinazoline derivs. represented by general formula (I) or pharmacol. acceptable salts thereof [wherein R1A and R1B are the same or different and each represents hydrogen, lower alkyl, lower alkoxy, halogeno, nitro, NR3R4 (wherein R3 and R4 are the same or different and each represents hydrogen or lower alkyl), etc.; or R1A may form together with R1B adjacent thereto O(CH2)nO (wherein n is 1 or 2); Cy represents optionally substituted aryl; R2 represents hydrogen or optionally substituted lower alkyl; and A represents hydrogen or optionally substituted lower alkyl, optionally substituted cycloalkyl, etc.; or R2 and A may form together with the nitrogen atom adjacent thereto an optionally substituted heterocycle]. These compds. exhibited insulin secretion activity at high concentration of glucose (14.5 mM) but no substantial activity at low concentration of glucose (≤5 mM). For comparison, glubenclamide did exhibit substantial insulin-secretion activity at low concentration of glucose. Thus, 7-chloro-7-methoxy-2-[2-(E)-(2,4-dimethoxyphenyl)vinyl]quinazoline was condensed with N-methylphenethylamine to give the title compound (II). II in vitro showed insulin secretion activity of 3,413 ng/mL at 1 μM under 14.5 mM glucose and 86 ng/mL at 10 μM under 5 mM glucose in spleen β-cells (MIN6) as compared to that of 684 ng/mL at 0.1 μM under 14.5 mM glucose and 317 ng/mL at 0.1 μM under 5 mM glucose for glubenclamide.
IT 221008-87-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of vinylaminoquinazoline derivs. as insulin secretion promoters and antidiabetics)
RN 221008-87-3 CAPLUS
CN Quinazoline, 2-[(1E)-2-(4-ethoxyphenyl)ethenyl]-7-methoxy-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:405511 CAPLUS
DOCUMENT NUMBER: 77:5511
TITLE: 2-Styryl-4-aminoquinazolines
INVENTOR(S): Breuer, Hermann; Schulze, Ernst
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2135172	A	19720120	DE 1971-2135172	19710714
US 3753981	A	19730821	US 1970-55252	19700715
CH 532056	A	19730215	CH 1971-532056	19710714
CA 971962	A1	19750729	CA 1971-118193	19710714
FR 2100916	A5	19720324	FR 1971-25952	19710715
FR 2100916	B1	19741018		
HU 163174	P	19730628	HU 1971-SU648	19710715
GB 1364294	A	19740821	GB 1971-33228	19710715

PRIORITY APPLN. INFO.: US 1970-55252 A 19700715

GI For diagram(s), see printed CA Issue.

AB The title compds. [I, R = NHCHMe(CH2)3NEt2, morpholino, or 4-methyl-1-piperazinyl; R1 = H, Cl, OMe, or NO2; R2 = H or Cl], useful as antiinflammatory agents, were prepared by treatment of 2-styryl-4(3H)-quinazolinones with POCl3 to give I (R = Cl) and reaction with amines. Thus, 28.3 g 6-chloro-2-styryl-4(3H)-quinazolinone was refluxed 4 hr with POCl3 in PhNMe2 and C6H6 to give I (R = Cl, R1 = 6-Cl, R2 = H). Similarly prepared were 8 I (R = Cl), e.g. (R1 and R2 given): 7-Cl, H (II); 6-OMe, Cl. Refluxing 8.4 g II 15 hr with H2NCHMe(CH2)3NEt2 in C6H6 gave 9.25 g I [R = NHCHMe(CH2)3NEt2, R1 = 7-Cl, R2 = H], from which the di-HCl salt was also prepared. Similarly prepared were 14 addnl. I, e.g. (R-R2 and salt given): morpholino, 7-Cl, Cl, -; 4-methyl-1-piperazinyl, 6-Cl, H, 1.5HCl.0.5H2O; NHCHMe(CH2)3NEt2, 7-OMe, H, 2HCl.2H2O.

IT 36945-47-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36945-47-8 CAPLUS

CN Quinazoline, 7-methoxy-4-(4-morpholinyl)-2-(2-phenylethenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)